High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.
High mobility group A1 (HMGA1) proteins are architectural transcriptional factors that are over-expressed in a wide range of human malignancies. Recently published evidence suggests HMGA1 is a promising candidate biomarker and therapeutic target in pancreatic cancer. This review summarises data implicating HMGA1 as an important mediator of progression in human cancer and in pancreatic cancer.
Department of Surgery, Addenbrooke's Hospital, Cambridge. liauss@doctors.org.uk
S S
SS
Liau
E
E
Whang
D000230:Adenocarcinoma / Q000235:genetics* / Q000628:therapy; D014408:Biomarkers, Tumor / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D025741:HMGA1a Protein / Q000235:genetics*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000628:therapy; D010641:Phenotype
D014408:Biomarkers, Tumor; D025741:HMGA1a Protein